The drugmaker on Friday said it would make investments in research laboratories and manufacturing sites, mostly geared toward the development of its diabetes treatments, according to the report.
Eli Lilly’s new strategy follows President Donald Trump’s call to bring manufacturing — for drugs and other products — back to the U.S.
CEO David Ricks said he’d make even more investments in the U.S. if the nation offered more favorable tax laws for companies, according to the report.
“The equitable treatment of foreign earnings, a lower U.S. corporate tax rate and U.S. innovation incentives — similar to the rest of the world — will encourage significant investment,” Mr. Ricks told Reuters.
More articles on supply chain:
Viewpoint: Why Americans are too focused on high drug costs
Sen. Sanders eager to partner with Trump on drug cost legislation
4 latest FDA approvals
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
